Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Details : 18-F FAPI-74 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastrointestinal Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
December 08, 2022
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
Details : 68-Ga FAPI-46 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : 68-Ga FAPI-46
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging
Details : [68Ga]FAPI-46 is the Gallium-68 radiolabeled PET tracer consisting of FAPI -46 precursor small molecule critical drug intermediate consisting of a FAPI moiety conjugated with a DOTA chelator.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : 68-Ga FAPI-46
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable